| Detected | Trial | Change |
|---|---|---|
| 2026-08-15 | NCT07543536 Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer |
Recruitment opened |
| 2026-08-14 | NCT06712888 Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced… |
Enrollment closed, study ongoing |
| 2026-08-14 | NCT06712888 Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced… |
Trial sites expanded: 1 -> 10 locations |
| 2026-08-14 | NCT06712888 Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced… |
date change Primary completion moved earlier: 2030-01-01 -> 2028-11-26 |
| 2026-08-14 | NCT06712888 Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced… |
date change Completion moved earlier: 2032-01-01 -> 2030-11-26 |
| 2026-08-13 | NCT05979961 Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal… |
Enrollment closed, study ongoing |
| 2026-08-13 | NCT05979961 Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal… |
date change Primary completion pushed: 2026-09 -> 2029-03-05 |
| 2026-08-13 | NCT05979961 Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal… |
date change Completion pushed: 2029-09 -> 2031-03-05 |
| 2026-08-09 | NCT06018714 Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study |
overall status: Recruiting → Unknown |
| 2026-08-09 | NCT05930665 Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line… |
overall status: Recruiting → Unknown |
| 2026-08-08 | NCT06673693 Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma |
Enrollment closed, study ongoing |
| 2026-08-04 | NCT06281886 Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib… |
Trial completed |
| 2026-08-04 | NCT06281886 Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib… |
date change Primary completion moved earlier: 2026-12-01 -> 2026-06-25 |
| 2026-08-04 | NCT06281886 Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib… |
date change Completion moved earlier: 2026-12-01 -> 2026-06-25 |
| 2026-08-04 | NCT06139419 The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by… |
Trial completed |
| 2026-08-04 | NCT06139419 The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by… |
date change Primary completion moved earlier: 2026-08-30 -> 2026-06-30 |
| 2026-08-04 | NCT06139419 The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by… |
date change Completion moved earlier: 2026-08-30 -> 2026-06-30 |
| 2026-08-02 | NCT06736678 Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy… |
overall status: Recruiting → Unknown |
| 2026-08-02 | NCT06511661 Prognostic Significance of the Uncertain Resection in NSCLC |
overall status: Active, Not Recruiting → Unknown |
| 2026-08-02 | NCT06090656 Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial… |
overall status: Recruiting → Unknown |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-08-10 | NCT07756177 Guangzhou Preterm and Term Birth Cohort Study | Active, Not Recruiting | |
| 2026-08-10 | NCT07756190 Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly… | Phase 2 | Not Yet Recruiting |
| 2026-08-07 | NCT07751055 Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1… | Phase 2 | Recruiting |
| 2026-08-07 | NCT07753642 Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper… | Phase 2 | Not Yet Recruiting |
| 2026-08-06 | NCT07750067 Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant… | Phase 2 | Recruiting |
| 2026-08-04 | NCT07745257 Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative… | Phase 2 | Not Yet Recruiting |
| 2026-07-29 | NCT07732491 Culmerciclib in HR+/HER2+ Advanced Breast Cancer | Phase 2 | Recruiting |
| 2026-07-27 | NCT07729592 Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome | Phase 2 | Not Yet Recruiting |
| 2026-07-27 | NCT07729605 FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC | Phase 3 | Not Yet Recruiting |
| 2026-07-20 | NCT07714447 Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line… | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06624696 | Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at… | Respiratory Hypersensitivity | Recruiting |
| NCT02785380 | Laparoscopic Surgery VS RFA for Recurrent HCC | Hepatocellular Carcinoma | Not Yet Recruiting |
| NCT06770088 | Vunakizumab in Adults with Spondyloarthritis | Spondyloarthritis (SpA) | Not Yet Recruiting |
| NCT06437288 | Hematoporphyrin Photodynamic Therapy for Esophageal Cancer | Esophageal Cancer | Enrolling by Invitation |
| Phase 3 | |||
| NCT03368651 | The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients… | Hepatocellular Carcinoma | Recruiting |
| NCT03561740 | A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High… | Breast Cancer | Recruiting |
| NCT03671252 | Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy… | Rectal Cancer | Recruiting |
| NCT04136886 | Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | Recruiting |
| NCT01649830 | Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma | Astrocytoma | Recruiting |
| NCT04448522 | Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for… | Nasopharyngeal Carcinoma | Recruiting |
| NCT04453813 | Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent… | Nasopharyngeal Carcinoma | Recruiting |
| NCT04453826 | Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk… | Nasopharyngeal Cancer | Recruiting |
| NCT04778956 | Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal… | Nasopharyngeal Carcinoma | Recruiting |
| NCT04799002 | Topotecan and Melphalan for Retinoblastoma | Retinoblastoma | Recruiting |
| NCT05080010 | Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma | Retinoblastoma | Recruiting |
| NCT05194878 | Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers | Colon Cancer Stage II | Recruiting |
| NCT05044117 | Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) | Head and Neck Squamous Cell Carcinoma | Recruiting |
| NCT05342792 | Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk… | Nasopharyngeal Carcinoma | Recruiting |
| NCT05367206 | Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC… | Cervical Cancer | Recruiting |
| NCT05476432 | HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a… | Hepatocellular Carcinoma | Recruiting |
| NCT05236972 | PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer | Colorectal Carcinoma | Recruiting |
| NCT05768490 | Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR… | Brain Metastases | Recruiting |
| NCT05768503 | Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced… | Metastatic Microsatellite-stable Colorectal Cancer | Recruiting |
| NCT05854849 | Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of… | Nasopharyngeal Carcinoma | Recruiting |
| NCT05794971 | Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver… | Colorectal Cancer Liver Metastases | Recruiting |